ILMN — Stock Film
STOCK FILMSCENE 1/11ILMN · $190
Stock Expert AI presents
ILMN
Illumina, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Illumina, Inc. A quick introduction.

On the stock market since 2000, it operates in the world of health and science. It has 8,600 employees. Now — the numbers.

on the stock market since 2000
8,600 employees
$29B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $20 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 20%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
92%Sequencing
Sequencing 92%Microarray 8%
92% of all revenue comes from a single line: Sequencing.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are moving sideways.

No real growth (-1% a year). Red columns mark years that ended in a loss.

$4.5B
2022
$4.6B
2023
$4.5B
2023
$4.4B
2024
$4.3B
2025
Cash on hand:
$0
Total debt:
$0
The debt outweighs the cash.

The gap is $920M. In times of high interest rates, a gap like that can squeeze a company.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
94
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
51
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
65
strong

Clearly above the class average — a step short of the very top.

GROWTH
83
very strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
85
very strong

The stock has been running stronger than the market lately.

No real weak spot in any of the five subjects — a balanced report card.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 63% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
A fat but narrowing margin

The net profit margin is 20% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/2
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/3
Sales are shrinking

Over the last 3 years, sales fell about 1% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

2
THE RISKS · 2/3
A rich price tag

The company’s market value is 34 times its annual profit. Even a small disappointment could hit the price hard.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 13% above the average analyst price target.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, ILMN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: ILMN is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film